Loading...
Loading...
Boehringer
Ingelheim and Eli Lilly and Company
today announced the European
Medicines Agency (EMA) has accepted for review a marketing authorization
application (MAA) for the investigational sodium glucose co-transporter-2
(SGLT2) inhibitor empagliflozin*, for the treatment of type 2 diabetes
mellitus (T2D) in adults. The acceptance of the MAA marks the beginning of the
review process in the European Union for this potential oral diabetes
treatment.
"We are pleased the EMA has accepted our marketing authorization application
for a potential new treatment option to help patients better manage their type
2 diabetes mellitus," said Prof. Klaus Dugi, Corporate Senior Vice President
Medicine, Boehringer Ingelheim. "More than 300 million people worldwide live
with type 2 diabetes mellitus and varied approaches to treating this condition
are needed to help these patients better manage their condition."
A New Drug Application for empagliflozin was recently submitted to the Food
and Drug Administration (FDA) in the United States for the treatment of T2D in
adults.
Empagliflozin is a member of the SGLT2 inhibitor class of drugs being
investigated for the reduction of blood glucose levels in adults with T2D. The
emerging SGLT2 inhibitor class removes excess glucose through the urine by
blocking glucose re-absorption in the kidney.
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in